Meningioma (SSTR / DOTATATE Imaging)

Quick Answer

Meningiomas — the most common primary intracranial tumor (extra-axial, dural-based) — strongly overexpress somatostatin receptor subtype 2 (SSTR2), making Ga-68-DOTATATE PET highly sensitive and specific. Its highest-value roles are radiotherapy target-volume delineation (it defines tumor extent — especially osseous invasion, skull-base, and post-operative/en-plaque disease — better than MRI alone), distinguishing residual/recurrent tumor from post-treatment change, and detecting multifocal meningiomatosis. For refractory/aggressive meningioma, ¹⁷⁷Lu-DOTATATE (PRRT) is under investigation — the same SSTR theranostic logic as neuroendocrine tumors.

Background

Meningiomas arise from arachnoid cap cells, are usually dural-based and extra-axial, and are graded WHO 1 (benign, ~80%), 2 (atypical), 3 (anaplastic/malignant). Most are managed by observation, surgery, and/or radiotherapy. The nuclear-medicine contribution is not primary diagnosis (MRI does that) but precise extent, treatment planning, and post-treatment assessment, exploiting near-universal SSTR2 expression.

Why SSTR/DOTATATE

• SSTR2 overexpression is present in the large majority of meningiomas across grades → intense, specific DOTATATE uptake with very low normal brain background (unlike FDG's high cortical uptake).
• This high tumor-to-background makes DOTATATE excellent for delineating small, flat (en-plaque), skull-base, and bone-invading tumor that blends with dura/bone on MRI.

Clinical Applications

• Radiotherapy target-volume delineation — DOTATATE-defined tumor changes the RT volume in a substantial fraction of cases (captures osseous/skull-base extent MRI underestimates); increasingly standard for complex/skull-base meningioma planning.
• Residual/recurrent vs post-treatment change — DOTATATE uptake indicates viable tumor where MRI enhancement is ambiguous after surgery/RT.
• Multifocal disease / meningiomatosis and NF2-associated tumors — mapping burden.
• Grading/prognosis adjunct — higher-grade meningiomas tend to be more FDG-avid (FDG complements DOTATATE for aggressiveness), and reduced/heterogeneous SSTR can accompany dedifferentiation.

Therapy (investigational)

¹⁷⁷Lu-DOTATATE PRRT (and other SSTR-directed approaches) is being studied for treatment-refractory, progressive, or unresectable meningioma — leveraging the SSTR2 target, though not yet standard of care.

Interpretation & Pitfalls

• Physiologic uptake: pituitary gland and dural venous sinuses normally take up DOTATATE — do not mistake for tumor; correlate with MRI.
• Dural metastases and other SSTR-expressing lesions can also be DOTATATE-avid (differential of a dural-based avid lesion).
• DOTATATE is for extent/viability, not for making the initial diagnosis (MRI-based).

Reporting Checklist

• Report tumor extent (including osseous/skull-base involvement) relevant to RT planning or surgery.
• State viable tumor vs post-treatment change where MRI is equivocal.
• Attribute physiologic pituitary/venous-sinus uptake explicitly.
• Note FDG avidity if performed (higher-grade/aggressive suggestion).

Board Pearls

Meningiomas strongly overexpress SSTR2, so Ga-68-DOTATATE PET is sensitive and specific with very low normal brain background. Its main roles are radiotherapy target-volume delineation (defining osseous/skull-base/en-plaque extent MRI underestimates), residual/recurrent tumor vs post-treatment change, and mapping multifocal disease — not primary diagnosis (that's MRI).

Physiologic pituitary and dural venous-sinus uptake are normal on DOTATATE — don't over-call them as tumor. Higher-grade meningiomas are more FDG-avid, so FDG complements DOTATATE for aggressiveness.

¹⁷⁷Lu-DOTATATE PRRT is under investigation for refractory/progressive meningioma — the same SSTR theranostic logic as NETs. The differential for a dural-based DOTATATE-avid lesion includes dural metastases and other SSTR-expressing tissue; correlate with MRI and clinical context.

Related Pages

• Tracers: DOTATATE, FDG; related: brain tumor PET, neuroendocrine tumors (shared SSTR biology); therapy: ¹⁷⁷Lu-DOTATATE.

Figure / Diagram Suggestions

• A DOTATATE-defined RT target vs MRI-only volume (osseous/skull-base extent).
• A physiologic uptake map (pituitary, venous sinuses) vs tumor.

Differential Diagnosis

• Dural metastases (especially neuroendocrine, breast, or prostate primaries) can express SSTR and mimic meningioma — multiplicity and a known primary favor metastasis.
• Solitary fibrous tumor / hemangiopericytoma — a dural-based MRI mimic with variable, often lower SSTR uptake.
• At the cerebellopontine angle, DOTATATE helps separate an avid meningioma from a typically low-uptake vestibular schwannoma.
• Inflammatory/granulomatous pachymeningitis (neurosarcoidosis, IgG4-related disease) can cause dural uptake mimicking en-plaque meningioma.
• Other skull-base SSTR-avid tumors (paraganglioma, olfactory neuroblastoma) enter the differential by location.

Self-Check